Reliant's Antara Launch Set For First Quarter, Omacor Will Be Later
This article was originally published in The Pink Sheet Daily
Executive Summary
The cholesterol products have the potential to transform the company by generating annual sales of $150 mil. each, CEO Ernest Mario says. Reliant is considering possible combinations for Omacor; options include Antara or a statin.
You may also be interested in...
Reliant Launches Omacor With Existing Sales Force
Reliant had hoped to hire 200 additional reps to support launch of the omega-3 product, which was approved in 2004.
Reliant Launches Omacor With Existing Sales Force
Reliant had hoped to hire 200 additional reps to support launch of the omega-3 product, which was approved in 2004.
Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma
Fournier's co-marketing agreement with Abbott for the lipid-lowering product will remain unchanged following Solvay's €1.3 bil. acquisition of the French company. Solvay will build a new cardio-metabolic division from Fournier, to be headquartered in Paris.